Skip to main content

Table 2 The risk of bias of included trials

From: Effectiveness and safety research of Qingfei Paidu (QFPD) in treatment of COVID-19: an up-to-date systematic review and meta-analysis

References

A

B

C

D

E

F

G

H

Geng LM et al. [15]

?

?

?

?

 + 

 + 

 + 

L

Li KY et al. [17]

?

?

 + 

?

?

 + 

?

L

Li YD et al. [18]

 + 

?

?

?

?

 + 

?

L

Sun TF et al. [19]

 + 

?

 + 

 + 

?

 + 

 + 

M

Wang QL et al. [25]

 + 

?

−

?

 + 

 + 

?

M

Wang Y et al. [14]

 + 

?

−

?

?

 + 

?

M

Xin SY et al. [20]

?

?

−

?

?

 + 

?

M

Xu TL et al. [28]

?

?

 + 

?

?

 + 

?

L

Yang M et al. [29]

?

?

−

?

?

 + 

 + 

M

Yu HY et al. [21]

?

?

?

 + 

?

 + 

?

L

Yu XY et al. [26]

?

?

 + 

?

?

 + 

 + 

L

Zeng XH et al. [24]

 + 

?

?

?

?

 + 

?

L

Zhang LH et al. [27]

 + 

?

 + 

?

?

 + 

 + 

L

Zhang P et al. [22]

?

?

?

?

?

 + 

?

L

Zhen L et al. [23]

 + 

?

 + 

?

?

 + 

 + 

L

  1. A Random sequence generation; B Allocation concealment; C Blinding of participants and personnel; D Blinding of outcome assessment; E Incomplete outcome data; F Selective reporting; G Other bias; + Low risk;—High risk; ? Unclear; L Low; MMedium